AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05632536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SACRAL ESP AND CAUDAL BLOCK
Description: Application of ultrasound-guided sacral erector spinae plane (ESP) block or ultrasound-guided caudal block with 1mL/kg 0.25% bupivacaine (local anesthetic) to patients
Study NCT06623617 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control group：Health education
Description: Provide participants with health education, which is conducted one-on-one by researchers during the recruitment of mothers. The content includes the etiology and risk factors of PPSUI (Pelvic Organ Prolapse during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing techniques, as well as the implementation methods.
Study NCT06683651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STN1013800 ophthalmic solution
Description: Investigational Product: 0.1% STN1013800 ophthalmic solution
Study NCT06683651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Description: Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
Study NCT06682312 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive blood pressure
Description: Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor
Study NCT06618456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR dive (with Hypnosis)
Description: Participants experience a VR dive through a friendly underwater world. They get a trance induction via audio.
Study NCT06618456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR dive (without Hypnosis)
Description: Participants experience a VR dive through a friendly underwater world. They are informed that this part of the VR is a familiarization phase to the VR and they do not get a trance induction.
Study NCT06618456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Height exposure
Description: The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.
Study NCT06618456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Height exposure
Description: The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.
Study NCT06622356 — intervention group
Intervention type: OTHER
Intervention: MRI with Eovist
Description: The study was retrospective and did not design an intervention
Study NCT06624176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionix ShotBlocker
Description: This is a hospital-approved device used as standard-of-care in older children and adults to reduce pain during painful procedures. It is not considered established standard-of-care in the infant cohort.
Study NCT06624176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: Standard of care swaddling
Study NCT06624176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Swaddling
Description: Standard of care swaddling
Study NCT06624176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose administration
Description: Standard of care sucrose administration
Study NCT06624176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose administration
Description: Standard of care sucrose administration
Study NCT06624176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masimo Rad-97 Oximeter probe
Description: Oximeter probe
Study NCT06624176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Masimo Rad-97 Oximeter probe
Description: Oximeter probe
Study NCT01048983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
Study NCT06625996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate loading
Description: Preoperative carbohydrate loading
Study NCT06625996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: carbohydrate loading
Description: Preoperative carbohydrate loading
Study NCT06625879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block (SAPB)
Description: Group I: (Serratus Anterior Plane Block (SAPB) Group) (n=15):~The patient will lay on her side with arm brought forward, the linear US transducer probe (10-12 MHz) will be placed in the midaxillary line and then moved caudal from second rib until the sixth intercostal space. At this point, the subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction. In-plane technique will be used until the tip of the needle placed between the serratus anterior muscle and the external intercostal muscle (deep SABP) . A volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection.
Study NCT06625879 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Midpoint transverse process to pleura (MTP) block
Description: In the lateral postion, the T4 spine will be counted by ultrasound, and high frequency linear US transducer probe (10-12 MHz) will be placed longitudinally, approximately 2.5 cm lateral to the midline the needle will be advanced in plane from cranial to caudal direction. The desired end point for the needle tip will be the midpoint of the line between the posterior border of the transverse process of T4 and the pleura(injection will be deep (anterior) to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligment),the needle tip dose not enter the paravertebral space , a volume of titrated bolus of 20 ml of bupivacaine 0.5% will be injected after aspiration to avoid intravascular injection,pleural displacement and bowing of erector spinae will be observed at the side of injection .
Study NCT06624397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAREFREE Carer's Programme
Description: This programme was developed to provide carers with an opportunity to develop an understanding of Anorexia from a Biopsychosocial framework, taking into account the complex array of biological, psychological and social/environmental factors associated with the development and maintenance of this disorder. CAREFREE programme is unique in its focus on providing a framework for understanding AN from a Schema - Compassion Focused framework, incorporating psychoeducation in regard to both Anorexia Nervosa and Carer Burnout. The programme has a relational focus, with an emphasis on improving emotional fluency, family communication skills and self-other compassion.
Study NCT06626217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting conditions
Description: The volunteers hand is at rest and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch
Study NCT06626217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement artifacts
Description: The volunteer periodically spreads his/her fingers and clenches them into a fist, and Perfusion index readings are taken for six minutes from pulse oximeter and smartwatch.
Study NCT06626217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulation constriction
Description: The volunteers arm is constricted using a cuff to measure non-invasive blood pressure. The perfusion index value is monitored during the time of cuff pressure and cuff release. The measurement is followed by a 4-minute pause to allow the vascular supply to stabilize. The measurement is repeated three times.
Study NCT06626217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The volunteer is seated on the exercise bike, rests his forearms on the handlebars and is instructed not to move his arms. The volunteer\&#39;s heart rate is controlled to increase to 120 beats per minute. For five minutes, the perfusion index is recorded from a pulse oximeter and smartwatch.
Study NCT06624813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted partial prostatectomy
Description: Focal therapy with surgery for single lobe prostate cancer, partial robot-assisted partial prostatectomy
Study NCT06625736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical
Description: The Xenical group will receive identical capsules 120mg (one capsule) to be taken three times daily with meals, equaling 360mg total daily dose, which aligns with the usage in adult female patients
Study NCT06625736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The dandelion extract
Description: The dandelion extract group will receive 500 mg capsules of dandelion leaf extract, given 3 times per day before meals.
Study NCT06625749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accurasee™ IOPCL
Description: Intraocular pseudophakic capsular lens (IOPCL)
Study NCT06130813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: increased perioperative communication program
Description: Thanks to this communication program, informative content (8 times) will be shared with patients.
Study NCT05056064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral exercise
Description: exercise remain tongue
Study NCT05115019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI® vaccine
Description: Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
Study NCT05115019 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological serum, 0.9% NaCl, will be used as a placebo
Study NCT06623812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake
Description: Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality
Study NCT06326996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Participants will be given an infusion of thiamine.
Study NCT06326996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given an infusion of the placebo treatment.
Study NCT05551546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Medicine Health Coaching for Elimination Diet for Elimination Diet
Description: All participants will receive 5 coaching sessions to support them through the elimination diet.~First session: The foundation session is where the coach and participant begin to develop rapport and outline the participant's goals. This occurs before the start of the Elimination Diet for motivation, expectations, education, and preparation.~Second session: This can occur during week 1 of the elimination diet to support working through the implementation.~Third session: This session is recommended to occur during week 3 of the diet to prepare for the reintroduction of foods.~Fourth session: A session is recommended while the participant is reintroducing foods as this is typically the most difficult part of the diet as participants may be experiencing symptoms to reactive foods.~Fifth session: A wrap up session is recommended after all of the food re-introductions to support the participant with maintenance, goals to move forward, and reflection.
Study NCT01048983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Questionnaire
Description: Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
Study NCT05551546 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-guided Elimination Diet
Description: The Elimination Diet course materials include self-guided materials designed to guide participants through all phases of a comprehensive elimination diet, including preparation, elimination, and reintroduction phases.~All participants in this wait-list control group will be presented via email with the opportunity to receive the five sessions of coaching (described above) at the conclusion of the study.
Study NCT05241561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be prescribed following its Marketing Authorization with an initiation at a reduced dose of 40 mg per day. The dose will be adjusted according to safety.~At the end of the first cycle, patients may be eligible for an increase in the dose of cabozantinib (up to 60 mg per day) if the following criteria are met: no adverse effects of grade 3 or 4 cabozantinib-related, no dose reduction or interruption for safety reasons, no long-lasting grade 2 cabozantinib-related adverse effects requiring maximum supportive care. Continuation to 40 mg per day or reduction to 20 mg per day are the other alternatives depending on the safety profile.
Study NCT05241561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: biomonitoring and pharmacokinetics
Study NCT05241561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires of quality of life
Description: FKSI-19 and FKSI-DRS and EUROQOL EQ-5D-5L
Study NCT05210114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Hydration Sensor
Description: The device is a skin hydration sensor. The sensor is placed on the skin at the inner arm. It is non-invasive and measures in seconds the percent water content of the dermis by quantifying its dielectric constant.
Study NCT05599139 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low iodine diet
Description: Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.
Study NCT06066723 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: 19F MRI
Description: Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
Study NCT06293989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 5mg
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam 5 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
Study NCT06293989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam10 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
Study NCT06293989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
Study NCT04910815 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Atmo Gas Capsule
Description: The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
Study NCT04910815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atmo Gas Capsule
Description: The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
Study NCT04910815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atmo Gas Capsule
Description: The Atmo gas capsule is an ingestible electronic device. This capsule consists of gas and temperature sensors, electronic circuits, radio transmitter and silver oxide batteries. It can measure the concentrations and types of intestinal gases in individuals and give an indication of gut transit time. This data is used for research purposes to gain an understanding of the microbiota's localised functionality. The data from the sensors is transmitted out of the body over the radio frequency to a handheld receiver. The capsule passes out of the human body at the end of the measurement and is disposable.
Study NCT04910815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Breath Test
Description: Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
Study NCT04910815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Breath Test
Description: Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
Study NCT04910815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Fructoolifosaccharides (FOS) Breath Test
Description: FOS is a long chain carbohydrate that can only be broken down by bacteria with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
Study NCT04910815 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fructoolifosaccharides (FOS) Breath Test
Description: FOS is a long chain carbohydrate that can only be broken down by bacteria with hydrogen gas as a by-product. The hydrogen produced through fermentation is measured in the patients exhaled breath
Study NCT04910815 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Jejunal Aspiration and culture
Description: Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
Study NCT04910815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal Aspiration and culture
Description: Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
Study NCT04910815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal Aspiration and culture
Description: Endoscopic procedure to determine microbial load of the Small bowel. This is the gold standard to determine the Active SIBO cases
Study NCT04910815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin (550g) 1 capsule twice a day for 14 days.
Study NCT04910815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomised administration of either placebo or Rifaximin (550g) 1 capsule twice a day for 14 days. The placebo will be encapsulated maize starch and pregelatinised maize starch
Study NCT05847322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bordetella pertussis B1917
Description: The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Pertactin (PRN), Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.
Study NCT05847322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Pill
Description: A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
Study NCT05847322 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin Pill
Description: A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected